MAP2K7 and hepatocellular carcinoma: In hepatocellular carcinoma, YTHDF2 suppresses the mitogen-activated protein kinase 1 (ERK)/mitogen-activated protein kinase 7 (MEK) signaling pathway by reducing EGFR expression and subsequently inhibits cancer cell proliferation and growth [108].